Nu Skin Enterprises Inc. Common Stock (NUS)

FairStock Score: 75/100 — HIGH CONVICTION

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a value investor, I start with the business. Nu Skin sells skin care and wellness products worldwide. The record is not reassuring. Revenue fell from $2.0B in FY2023 to $1.7B in FY2024 to $1.5B in FY2025. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $320.1M and net income was -$249.8M, or -$5.14 per diluted share. That is a dramatic reversal from fiscal Q1 2026 net income of $1.8M and fiscal Q2 2025 net income of $21.1M. FY2025 net income was $160.2M, or $3.18 per diluted share, so the latest loss raises serious questions about earnings quality and stability. The moat, if any, is not visible in these numbers. Beauty and wellness distribution is competitive. FairStock says the Lynch category is TURNAROUND, because the company returned to profit after a loss within the last three years. But a turnaround needs durable profit, not one good year followed by a huge loss. At the close on 2026-10-13, the price was $5.01. FairStock's negative P/E makes earnings-based valuation useless. P/B is 0.45, so the market values the company at less than half its book value. Debt-to-equity is 0.53, Altman Z-Score 2.87, Piotroski 4/9, and ROE -32.53%. TTM FCF was $10.8M, a 4.4% FCF yield, and the dividend yield is 5.24%. Graham would demand a margin of safety and a reliable earnings record. Here, the asset discount is tempting, but the loss, falling revenue, and weak quality score mean the cheapness may be deserved until the business stabilizes.

In plain English: Nu Skin sells skin care and wellness products around the world. The business looks weak right now: sales are falling and the latest quarter showed a very large loss. The stock price looks low compared with the company's net assets, but that cheapness comes with real uncertainty.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer